Alchemia, Inc.

Alchemia Limited is a listed Australian biotechnology company (ASX:ACL). The Company has particular expertise in chemistry, which it has applied to the discovery and development of human therapeutic products.

Alchemia's antithrombotic drug, generic fondaparinux, is the Company's near term opportunity that targets the multi-billion dollar heparin-drug market and is expected to be generating revenues for the company in 2012.

HA-irinotecan is Alchemia's most advanced anticancer product and is expected to begin Phase III clinical trials in 2011. It is produced with Alchemia's HyACT technology which combines the chemotherapeutic drug irinotecan (Pfizer's Camptosar) with hyaluronic acid (HA). In May 2007, Alchemia reported exceptional results from a Phase II clinical trial: HA-irinotecan not only allowed more cycles of irinotecan to be administered to cancer patients, but also produced statistically significant disease control and a doubling in progression free survival.

Alchemia's VAST drug discovery platform targets G-protein coupled receptors (GPCRs). Currently half of the drugs on the market target GPCRs, and represent over US$100 billion in sales. VASTTM a revolutionary drug discovery technology with several drug candidates in early stages of development. The key advantage to this technology is that it can be applied to almost any target and the structure of the target does not need to be known.